146 related articles for article (PubMed ID: 17449943)
1. Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis.
Yoo J; Jung JH; Lee MA; Seo KJ; Shim BY; Kim SH; Cho DG; Ahn MI; Kim CH; Cho KD; Kang SJ; Kim HK
J Korean Med Sci; 2007 Apr; 22(2):318-25. PubMed ID: 17449943
[TBL] [Abstract][Full Text] [Related]
2. Expression of bcl-2 protein in non-small cell lung cancer: correlation with clinicopathology and patient survival.
Laudanski J; Chyczewski L; Niklińska WE; Kretowska M; Furman M; Sawicki B; Nikliński J
Neoplasma; 1999; 46(1):25-30. PubMed ID: 10355530
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers.
Hommura F; Dosaka-Akita H; Mishina T; Nishi M; Kojima T; Hiroumi H; Ogura S; Shimizu M; Katoh H; Kawakami Y
Clin Cancer Res; 2000 Oct; 6(10):4073-81. PubMed ID: 11051259
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of Bcl-2 and cyclin A2 on adverse recurrence-free survival in stage I non-small cell lung cancer.
Ko E; Kim Y; Cho EY; Han J; Shim YM; Park J; Kim DH
Ann Surg Oncol; 2013 Mar; 20(3):1005-12. PubMed ID: 23115005
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value study of lung cancer molecular markers].
García Luján R; Conde Gallego E; López Ríos F; Martín De Nicolás JL; Sánchez Céspedes M; García Quero C; López Encuentra A
Med Clin (Barc); 2009 Apr; 132(14):529-36. PubMed ID: 19368933
[TBL] [Abstract][Full Text] [Related]
8. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.
Volm M; Koomägi R
Br J Cancer; 2000 May; 82(10):1747-54. PubMed ID: 10817513
[TBL] [Abstract][Full Text] [Related]
9. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer.
Cooper WA; Kohonen-Corish MR; McCaughan B; Kennedy C; Sutherland RL; Lee CS
Histopathology; 2009 Jul; 55(1):28-36. PubMed ID: 19614764
[TBL] [Abstract][Full Text] [Related]
10. A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis.
Dosaka-Akita H; Hommura F; Mishina T; Ogura S; Shimizu M; Katoh H; Kawakami Y
Cancer Res; 2001 Mar; 61(6):2500-4. PubMed ID: 11289121
[TBL] [Abstract][Full Text] [Related]
11. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers.
Monzó M; Rosell R; Felip E; Astudillo J; Sánchez JJ; Maestre J; Martín C; Font A; Barnadas A; Abad A
J Clin Oncol; 1999 Jul; 17(7):2100-4. PubMed ID: 10561264
[TBL] [Abstract][Full Text] [Related]
12. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance.
Brambilla E; Moro D; Gazzeri S; Brambilla C
J Pathol; 1999 Aug; 188(4):351-60. PubMed ID: 10440744
[TBL] [Abstract][Full Text] [Related]
13. Thyroid transcription factor-1 (TTF-1) expression in human lung carcinomas: its prognostic implication and relationship with wxpressions of p53 and Ki-67 proteins.
Myong NH
J Korean Med Sci; 2003 Aug; 18(4):494-500. PubMed ID: 12923324
[TBL] [Abstract][Full Text] [Related]
14. Reduced expression of cyclin D2 is associated with poor recurrence-free survival independent of cyclin D1 in stage III non-small cell lung cancer.
Ko E; Kim Y; Park SE; Cho EY; Han J; Shim YM; Park J; Kim DH
Lung Cancer; 2012 Aug; 77(2):401-6. PubMed ID: 22534667
[TBL] [Abstract][Full Text] [Related]
15. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers.
D'Amico TA; Massey M; Herndon JE; Moore MB; Harpole DH
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):736-43. PubMed ID: 10096969
[TBL] [Abstract][Full Text] [Related]
16. Tissue microarray analysis of Fas and FasL expressions in human non-small cell lung carcinomas; with reference to the p53 and bcl-2 overexpressions.
Myong NH
J Korean Med Sci; 2005 Oct; 20(5):770-6. PubMed ID: 16224150
[TBL] [Abstract][Full Text] [Related]
17. Association of p53/p21 expression and cigarette smoking with tumor progression and poor prognosis in non-small cell lung cancer patients.
Xie D; Lan L; Huang K; Chen L; Xu C; Wang R; Shi Y; Wu X; Wang L; Liu Y; Lu B
Oncol Rep; 2014 Dec; 32(6):2517-26. PubMed ID: 25333671
[TBL] [Abstract][Full Text] [Related]
18. Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis.
Yaren A; Oztop I; Kargi A; Ulukus C; Onen A; Sanli A; Binicier O; Yilmaz U; Alakavuklar M
Int J Clin Pract; 2006 Jun; 60(6):675-82. PubMed ID: 16805752
[TBL] [Abstract][Full Text] [Related]
19. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis.
Pelletier MP; Edwardes MD; Michel RP; Halwani F; Morin JE
Can J Surg; 2001 Jun; 44(3):180-8. PubMed ID: 11407827
[TBL] [Abstract][Full Text] [Related]
20. Immunocytochemical markers in stage I lung cancer: relevance to prognosis.
Pastorino U; Andreola S; Tagliabue E; Pezzella F; Incarbone M; Sozzi G; Buyse M; Menard S; Pierotti M; Rilke F
J Clin Oncol; 1997 Aug; 15(8):2858-65. PubMed ID: 9256129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
